MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-18-2023
Aptinyx Total Liabilities 2011-2026 | APTX
Annual Total Liabilities Aptinyx
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.4 M | 20.2 M | 4.7 M | 5.17 M | 6.3 M | 137 M | 27.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 137 M | 4.7 M | 32.7 M |
Quarterly Total Liabilities Aptinyx
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.7 M | 28.4 M | 27.4 M | - | 29.2 M | 20.2 M | 20.6 M | 3.41 M | 3.95 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 5.17 M | 5.17 M | 5.17 M | 5.17 M | 6.3 M | 6.3 M | 6.3 M | 6.3 M | 4.65 M | 4.65 M | 4.65 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 29.7 M | 3.41 M | 10.5 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M |  USA |
 |
AbbVie
ABBV
|
97.3 B | $ 232.08 | 3.29 % | $ 411 B | USA |
 |
AbCellera Biologics
ABCL
|
390 M | $ 3.61 | 0.56 % | $ 1.08 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
49.2 M | $ 5.12 | -1.54 % | $ 109 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
38.4 M | $ 4.66 | -0.85 % | $ 773 M | Canada |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 24.56 | -0.32 % | $ 4.07 B | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Achieve Life Sciences
ACHV
|
20.8 M | $ 4.56 | -3.59 % | $ 90.4 M | USA |
 |
AC Immune SA
ACIU
|
119 M | $ 2.93 | -1.01 % | $ 229 M |  Schweiz |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aclaris Therapeutics
ACRS
|
57.4 M | $ 2.87 | -8.31 % | $ 352 M | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
38.7 M | $ 2.96 | -4.67 % | $ 167 M | China |
 |
ADC Therapeutics SA
ADCT
|
440 M | $ 4.1 | -0.73 % | $ 105 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
976 K | $ 2.53 | - | $ 16.4 M | USA |
 |
ADMA Biologics
ADMA
|
147 M | $ 15.57 | 2.57 % | $ 3.71 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
288 M | $ 16.02 | -2.67 % | $ 2.43 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
ADiTx Therapeutics
ADTX
|
23.9 M | $ 0.46 | -4.63 % | $ 6.06 K | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Agenus
AGEN
|
387 M | $ 3.33 | -0.89 % | $ 1.19 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
104 M | $ 30.23 | 0.83 % | $ 1.75 B | USA |
 |
AIM ImmunoTech
AIM
|
3.29 K | $ 0.91 | -8.59 % | $ 43.8 M | USA |
 |
Akebia Therapeutics
AKBA
|
344 M | $ 1.31 | -0.76 % | $ 337 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
28.3 M | $ 0.24 | -8.87 % | $ 5.73 B | Britain |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Aldeyra Therapeutics
ALDX
|
27.8 M | $ 5.46 | -0.73 % | $ 328 M | USA |
 |
Alector
ALEC
|
263 M | $ 2.43 | -5.08 % | $ 250 M | USA |
 |
Aligos Therapeutics
ALGS
|
59.4 M | $ 7.03 | -6.27 % | $ 452 M | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Alkermes plc
ALKS
|
668 M | $ 30.1 | -2.05 % | $ 4.96 B |  Irlanda |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Allogene Therapeutics
ALLO
|
131 M | $ 2.78 | 1.83 % | $ 436 M | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 332.92 | 0.51 % | $ 43.6 B | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Altimmune
ALT
|
15.8 M | $ 4.31 | -3.36 % | $ 306 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
ALX Oncology Holdings
ALXO
|
34.2 M | $ 2.11 | -10.21 % | $ 110 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Amgen
AMGN
|
50 B | $ 388.16 | 2.33 % | $ 209 B | USA |
 |
Aileron Therapeutics
ALRN
|
7.8 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |